-+ 0.00%
-+ 0.00%
-+ 0.00%

Legend Biotech To Present Data For Its CARTITUDE-2 Trial Of CARVYKTI At 23rd International Myeloma Society Annual Meeting

Benzinga·09/10/2026 12:04:24
Listen to the news

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. The presentations will include updated long-term follow-up data from the CARTITUDE-2 clinical trial evaluating the safety and efficacy of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) across different multiple myeloma disease settings.